You are here: Industry Insights > Malaria

News List

Common Malaria Treatments David Orchard-Webb
December 01, 2023
Malaria is a mosquito-borne parasitic disease that causes high fever, severe chills, and sweating.
Vaccinating against Malaria in Africa SHEM OIRERE
August 15, 2023
Vaccinating against malaria is gaining traction among many countries in malaria-prone Africa region where four-year pilot scheme of administering a malaria vaccine on children has borne good results according to World Health Organization.
Zydus receives Orphan Drug Designation from US FDA for malaria treatment expresspharma
December 17, 2021
The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US.
GSK to provide malaria vaccines for Gavi eligible countries PharmaTimes
December 06, 2021
The new development will arm healthcare providers with a vital tool to address the steep rise of malaria cases in children living in Africa.
GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children FirstWordPharma
December 03, 2021
GlaxoSmithKline (GSK) plc today welcomed the decision of the Gavi Board to provide funding for the procurement and introduction of malaria vaccines into routine child immunisation programmes in Gavi eligible countries.
Monoclonal antibody prevents malaria in small NIH trial europeanpharmaceuticalreview
August 13, 2021
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
BioNTech Update on Sustainable Solutions to Infectious Disease in Africa americanpharmaceuticalreview
July 28, 2021
BioNTech SE announced the launch of its Malaria project, which aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent.
Modus Therapeutics partners with Imperial College London on malaria drug pharmatimes
June 16, 2021
Swedish biotech company Modus Therapeutics has announced a new collaboration with Imperial College London to research the effects of its drug sevuparin in patients with severe malaria.
Sanaria® PfSPZ-CVac vaccine 75 percent effective at preventing malaria europeanpharmaceuticalreview
June 11, 2021
Clinical studies optimising immunisation with Sanaria’s PfSPZ-CVac vaccine resulted in 77 and 75 percent of participants being protected from malaria infection.
Novartis announces delivery of one billion courses of anti-malarial treatment expresspharma
May 21, 2021
Along with malaria prevention tools and better diagnostics, ACTs remain a key component of the global drive to reach malaria elimination.

Previous page 1 2 3 4 5 6 7 Next page